{"paper_id": "0426d1cf12b4ef76fe82e003223bc3186a704c49", "metadata": {"title": "Protocol", "authors": []}, "abstract": [], "body_text": [{"text": "In early December 2019, the first pneumonia cases of unknown origins were identified in Wuhan city, Hubei province, China. High-throughput sequencing has revealed a novel betacoronavirus that is currently named 2019 novel coronavirus (2019-nCoV), which resembled severe acute respiratory syndrome coronavirus (SARS-CoV). The 2019-nCoV is the seventh member of enveloped RNA coronavirus (subgenus sarbecovirus, Orthocoronavirinae subfamily). Evidence pointing to the person-to-person transmission in hospital and family settings has been accumulating.", "cite_spans": [], "ref_spans": [], "section": "Study protocol Background"}, {"text": "The World Health Organization has recently declared the 2019-nCoV a public health emergency of international concern. As of February 5 th , 2020, 24,554 laboratory-confirmed cases have been documented globally (i.e., the USA, Vietnam, Germany). 28,018 laboratory-confirmed cases and 563 death cases in China as of February 6 th , 2020. Despite the rapid spread worldwide, the clinical characteristics of 2019-nCoV acute respiratory disease (ARD) remain largely unclear. In two recent studies documenting the clinical manifestations of 41 and 99 patients respectively with laboratoryconfirmed 2019-nCoV ARD who were admitted to Wuhan, the severity of some cases with 2019-nCoV ARD mimicked that of SARS-CoV.", "cite_spans": [], "ref_spans": [], "section": "Study protocol Background"}, {"text": "We sought to identify the defining epidemiological and clinical characteristics with greater precision, but also unravel the risk factors associated with mortality.", "cite_spans": [], "ref_spans": [], "section": "Objective"}, {"text": "The clinical characteristics of patients with 2019-nCoV in our study cohort might differ from those reported recently given the increased sample size; greater disease severity might be associated with an increased risk of reaching to the composite endpoint.", "cite_spans": [], "ref_spans": [], "section": "Hypothesis"}, {"text": "Retrospective study on the patients from provinces/autonomous regions/provincial municipalities across China. The time frame started from the 'first case' (November 2019) to the latest date when available (late January 2020).", "cite_spans": [], "ref_spans": [], "section": "Study design"}, {"text": "Cases will be diagnosed based on the WHO interim guidance. A confirmed case with 2019-nCoV ARD will be defined as a positive result to high-throughput sequencing or real-time reversetranscriptase polymerase-chain-reaction (RT-PCR) assay for nasal and pharyngeal swab specimens", "cite_spans": [], "ref_spans": [], "section": "Study participants Diagnostic criteria"}, {"text": "Only the laboratory-confirmed cases were included the analysis.", "cite_spans": [], "ref_spans": [], "section": "Inclusion criteria"}, {"text": "No exclusion criteria apply provided that the clinical profiles of the patients are as complete as possible, which would not prevent from the analysis of the composite endpoint.", "cite_spans": [], "ref_spans": [], "section": "Exclusion criteria"}, {"text": "The primary composite endpoint will be the admission to intensive care unit (ICU), or mechanical ventilation, or death. Secondary endpoints comprised mortality rate, the time from symptom onset to the composite endpoint and each of its component. Because clinical observations were still ongoing, fixed time frame (i.e. within 28 days) will not be applied to these endpoints.", "cite_spans": [], "ref_spans": [], "section": "Outcome assessment"}, {"text": "** The exposure to wildlife denote that a person in close contact with wildlife animals (bats, snakes, civet cats, etc.) or visiting either a wildlife retailer or a market selling wildlife within two weeks before the onset of respiratory symptoms. However, the cases with regular visit to the market without recalling the exposure date will not be considered as having definite exposure to the wildlife. ** Pneumonia will be diagnosed as an acute respiratory disorder characterized by the presence of cough and at least one of the new-onset focal chest signs, fever for more than 4 days or dyspnoea/ tachypnoea. ** Shock and acute respiratory distress syndrome (ARDS) will be defined in accordance with the WHO interim guidance. ** Acute kidney injury will be defined based on the highest serum creatinine level and urine output. Specifically, the diagnosis could be made based on any of the following criterion: an increase in serum creatinine levels by 0.3 mg/dl or greater (26.5 \u00b5mol/l or greater) within 48 hours; or increase in serum creatinine levels to 1.5 times of the baseline level or greater, which was known or presumed to have occurred within 7 days; or urine volume of below 0.5 ml/kg/h for 6 consecutive hours.", "cite_spans": [], "ref_spans": [], "section": "Definitions of exposure and clinical complications"}, {"text": "** The diagnosis of secondary bacterial or fungal infection will be made in case of the occurrence of hospital-acquired pneumonia or bacteremia, plus a positive result of new pathogen culture from the blood and lower respiratory tract specimen (including sputum, bronchoalveolar lavage fluid or tracheal aspirate) obtained at least 8 hours after admission. ** Acute heart failure will be defined as the clinical syndrome characterized by typical symptoms (e.g. breathlessness, ankle swelling and fatigue) that may be accompanied by signs (e.g. elevated jugular venous pressure, pulmonary crackles and peripheral edema) caused by a structural and/or functional cardiac abnormality.", "cite_spans": [], "ref_spans": [], "section": "Definitions of exposure and clinical complications"}, {"text": "** Rhabdomyolysis will be diagnosed if the muscle pain or muscle weakness took place on admission and the creatine kinase level was greater than 10 times the upper limit of normal.", "cite_spans": [], "ref_spans": [], "section": "Definitions of exposure and clinical complications"}, {"text": "In this study, the history of contact with wildlife will be documented through self-report by the patients. Among the patients who live outside Wuhan, the absolute count and percentage of patients who are the residents of Wuhan, patients who have a recent travel to Wuhan and patients who have a contact with people from Wuhan will be reported, respectively. A recent travel to, nor contact with people from, Wuhan will be inquired among the patients living outside of Wuhan.", "cite_spans": [], "ref_spans": [], "section": "Assessment of exposure"}, {"text": "Because all laboratory-confirmed cases will have to be reported to the National Health Commission which is the main coordinator of our study, our study population would not be derived from random sampling. Since early this January, the medical staff in Hubei (especially in Wuhan) suffered from a major burn-out of the workload given the rapid surge of cases. A team consisting of three experts of the lead site will be dispatched to Wuhan to assist in extracting the clinical data from the electronic hospital information system.", "cite_spans": [], "ref_spans": [], "section": "Sampling and sample size estimation"}, {"text": "No previous study has documented the percentage of patients who reach to the composite endpoint or either of the outcome variable. Hence, it would not be possible to estimate for the sample size based on literature reports. However, it is believed that the large sample sizes derived from hospitals across China would be sufficient to power the statistical analysis in our study.", "cite_spans": [], "ref_spans": [], "section": "Sampling and sample size estimation"}, {"text": "Data will be collected from the electronic medical records (EMR) or paper-based medical records that managed by the National Health Commission. All medical records will be transmitted or copied and sent to the data processing center in Guangzhou under the coordination of the National Health Commission. All needed variables with necessary explanations will be defined firstly by the research team. An experienced respiratory clinicians team will review the copies of the medical records and abstract the data. The abstracted data will be entered into a computerized database, and double-entry is required for all variables. The data-entry team ensures that all data needed are collected. If the core data were missing, requests of clarification will be immediately sent to the coordinators who subsequently contacted the attending clinicians. Data cleaning, including logical check, outlier check, and variables engineering, will be performed by experienced programmers. An experienced clinician will assist the variables engineering, the original variables will be transformed if need, which may include, but is not restricted to, converting continuous variables to categorical variables, and combining multiple variables into single variables for information integration.", "cite_spans": [], "ref_spans": [], "section": "Data management"}, {"text": "The convenience sampling method will be used because random sampling will not be feasible under the epidemic situation of 2019-nCoV. Sampling frame will include all hospitals which admit the patients with 2019-nCoV infection.", "cite_spans": [], "ref_spans": [], "section": "Statistical analysis plan Sampling"}, {"text": "The sample size will not be estimated based on the statistical power. We will collect as many cases as possible.", "cite_spans": [], "ref_spans": [], "section": "Sample size estimation"}, {"text": "\u2022 All tests are two-sided, the nominal level of type I error will be 5% and the confidence level for all confidence intervals will be 95%.", "cite_spans": [], "ref_spans": [], "section": "Analysis principles"}, {"text": "\u2022 There will be no imputing of missing values. The number of observations used in an analysis will be reported.", "cite_spans": [], "ref_spans": [], "section": "Analysis principles"}, {"text": "\u2022 Subgroup analyses will be carried out irrespective of whether there is a significant treatment effect on the primary outcome.", "cite_spans": [], "ref_spans": [], "section": "Analysis principles"}, {"text": "\u2022 Analyses will be conducted using R packages (version 3.6.2). Distribution map will be plotted by using ArcGis (version 10.2.2).", "cite_spans": [], "ref_spans": [], "section": "Analysis principles"}, {"text": "Flow chart of inclusion will be displayed in a diagram. The report will include the number of patients who met the inclusion criteria and the number of non-included patients. The distribution of laboratory-confirmed cases throughout china will also be reported by using a distribution map.", "cite_spans": [], "ref_spans": [], "section": "Trial profile"}, {"text": "Description and statistical inference of the patients' characteristics, radiographic and laboratory findings will be presented by the disease severity and the composite endpoint.", "cite_spans": [], "ref_spans": [], "section": "Patients characteristics and baseline comparisons"}, {"text": "Discrete variables will be summarized by frequencies and percentages. Percentages will be calculated according to the number of patients for whom data is available. Continuous variables will be summarized by median and 25%, 75% quartiles [Median (IQR)].", "cite_spans": [], "ref_spans": [], "section": "Patients characteristics and baseline comparisons"}, {"text": "Statistical inference of continuous variables will be performed using t-test or Wilcoxon rank-sum tests as appropriate. The Pearson's Chi-square test or Fisher exact test will be used, as appropriate, for categorical data.", "cite_spans": [], "ref_spans": [], "section": "Patients characteristics and baseline comparisons"}, {"text": "Baseline measures for all patients will be tabulated.", "cite_spans": [], "ref_spans": [], "section": "Patients characteristics and baseline comparisons"}, {"text": "For the primary outcome of time to the composite endpoint and other outcomes, the multivariable analysis will be performed by Fine-Gray competing-risk models in which recovery will be included as competing for risk. The candidate risk factors include exposure history, age, radiologic and laboratory findings, and the development of complications. Candidate risk factors that are of biological interest (age and sex) or clinical important (smoking status) or statistically significant will be included in the multivariable models. The sub-distribution hazard ratios with 95% confidence interval will be reported.", "cite_spans": [], "ref_spans": [], "section": "Outcomes"}, {"text": "Subgroup analyses will be carried out for the primary outcome.", "cite_spans": [], "ref_spans": [], "section": "Subgroup analysis"}, {"text": "Planned subgroup analysis:", "cite_spans": [], "ref_spans": [], "section": "Subgroup analysis"}, {"text": "\u2022 disease severity", "cite_spans": [], "ref_spans": [], "section": "Subgroup analysis"}, {"text": "The proportional hazard Cox model analysis will be conducted as sensitivity analyses.", "cite_spans": [], "ref_spans": [], "section": "Sensitivity analysis"}, {"text": "The study has been approved by the National Health Commission and the institutional board of each participating site. Written informed consent has been waived in light of the urgent need to collect clinical data. ", "cite_spans": [], "ref_spans": [], "section": "Ethics approval"}], "bib_entries": {"BIBREF0": {"ref_id": "b0", "title": "C-reactive protein level \u2265 10 mg/liter -No./total No. (%) Procalcitonin level \u2265 0.5 ng", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF1": {"ref_id": "b1", "title": "Aspartate aminotransferase > 40", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF3": {"ref_id": "b3", "title": "Creatinine \u2265 133 \u03bcmol", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}}, "ref_entries": {"FIGREF0": {"text": "reactive protein level \u2265 10 mg/liter -No./total No. (%) Procalcitonin level \u2265 0.5 ng/ml -No./total No. (%) Lactose dehydrogenase \u2265 250 U/liter -No./total No. (%) Aspartate aminotransferase > 40 U/liter -No./total No. (%) Alanine aminotransferase > 40 U/liter -No./total No. (%) Total bilirubin 17.1 \u03bcmol/liter -No./total No. (%) Creatinine kinase \u2265 200 U/liter -No./total No. (%) Creatinine \u2265 133 \u03bcmol/liter -No./total No. (%) D-dimer \u2265 0.5 mg/liter -No./total No. (%) Sodium -mmol/liter Potassium -mmol/liter Chloride -mmol/liter P values denoted the comparison between mild-moderate cases and severe cases.", "latex": null, "type": "figure"}, "FIGREF1": {"text": "Complications, treatment and clinical outcomes of patients with 2019", "latex": null, "type": "figure"}, "FIGREF2": {"text": "Summary characteristics of 2019-nCoV, SARS-CoV, MERS-CoV and highly pathogenic", "latex": null, "type": "figure"}, "TABREF0": {"text": "Clinical characteristics of the patients with 2019-nCoV", "latex": null, "type": "table", "html": "<html><body><table><tr><td>\u00a0</td><td>Clinical characteristics, symptoms or signs </td><td>All patients </td><td>Mild-moderate </td><td>Severe P value </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>N= </td><td>N= </td><td>N= </td></tr><tr><td>Age </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Median (range) - yrs </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Age groups - No., % </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>0-14 yrs </td><td>\u00a0</td><td>\u00a0</td><td>- </td></tr><tr><td>\u00a0</td><td>15-49 yrs </td><td>\u00a0</td><td>\u00a0</td><td>- </td></tr><tr><td>\u00a0</td><td>50-64 yrs </td><td>\u00a0</td><td>\u00a0</td><td>- </td></tr><tr><td>\u00a0</td><td>\u2265 65 yrs </td><td>\u00a0</td><td>\u00a0</td><td>- </td></tr><tr><td>Female sex - No.,% </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Current smokers - No., % </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Exposure to live poultry </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>Within previous 14 days - No., % </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>Median incubation time (IQR) - days </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Hospitalization - No., % </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>Recent travel to infected region - No., % </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>None </td><td>\u00a0</td><td>\u00a0</td><td>- </td></tr><tr><td>\u00a0</td><td>Hubei province </td><td>\u00a0</td><td>\u00a0</td><td>- </td></tr><tr><td>\u00a0</td><td>Elsewhere </td><td>\u00a0</td><td>\u00a0</td><td>- </td></tr><tr><td>Incubation period - days </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>Median (range) </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>On admission No./Total No. (%) </td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>Respiratory symptoms - No., % </td><td>- </td><td>- </td><td>- - </td></tr><tr><td>\u00a0</td><td>Fever </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>37.5-38.0\u2103 </td><td>\u00a0</td><td>\u00a0</td><td>- </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>38.1-39.0\u2103 </td><td>- </td></tr></table></body></html>"}, "TABREF1": {"text": "Radiographic and laboratory testing findings of 2019-nCoV", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Variables </td><td>All patients </td><td>Mild-moderate </td><td>Severe </td><td>P value </td></tr><tr><td>N= </td><td>N= </td><td>N= </td><td>\u00a0</td></tr><tr><td>Radiographic findings </td><td>- </td><td>- </td><td>- </td><td>- </td></tr></table></body></html>"}, "TABREF2": {"text": "Multivariate risk factors associated with the development of acute respiratory distress syndrome and mortality", "latex": null, "type": "table"}, "TABREF3": {"text": "", "latex": null, "type": "table"}, "TABREF4": {"text": "Clinical characteristics of patients with 2019-nCoV stratified by clinical outcomes Female sex -No.,% Current smokers -No., % Exposure to live poultry Within previous 14 days -No., % Median incubation time (IQR) -days Hospitalization -No., % Recent travel to infected region -No., %", "latex": null, "type": "table"}, "TABREF5": {"text": "Radiographic and laboratory testing findings of patients with 2019-nCoV stratified by clinical outcomes Abnormalities on chest X-ray -No./total No. (%) Abnormalities on chest CT -No./total No. (%) >10,000 per mm 3 -No., % <4,000 per mm 3 -No., % CD8+-T lymphocyte count -per mm 3 CD4:CD8 ratio <1.4 -No./total No. (%) Thrombocytopenia -No., %", "latex": null, "type": "table"}, "TABREF6": {"text": "Complications, treatment and clinical outcomes of patients with 2019-nCoV stratified by clinical outcomesAdministration of intravenous antibioticsTiming from onset of illness to antibiotic administrationAdministration of antifungal medicationsAdministration of systemic corticosteroidsMaximal corticosteroid dose > 0.1g per dayUse of extracorporeal membrane oxygenationUse of continuous renal replacement therapyUse of intravenous immunoglobin", "latex": null, "type": "table"}}, "back_matter": []}